BioNTech And Oncoc4 Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival Versus Standard-Of-Care Chemotherapy In Previously Treated Squamous Non-Small Cell Lung Cancer Patients
AstraZeneca Says Tagrisso (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial
BioNTech And Oncoc4 Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival Versus Standard-Of-Care Chemotherapy In Previously Treated Squamous Non-Small Cell Lung Cancer Patients
AstraZeneca Says Tagrisso (Osimertinib) Demonstrated Unprecedented Eight-Year Landmark Survival In Early-Stage EGFR-Mutated Lung Cancer In Adaura Phase III Trial